Department of Medicine, MacKay Medical College, New Taipei City, Taiwan.
Department of Medical Research, MacKay Memorial Hospital, New Taipei City, Taiwan.
J Orthop Surg Res. 2022 Jun 28;17(1):335. doi: 10.1186/s13018-022-03228-9.
Osteolysis is one of the most prevalent clinical complications affecting people who undergo total joint replacement (TJR). Wedelolactone (WDL) is a coumestan compound derived from the Wedelia chinensis plant and has been demonstrated to exhibit anti-inflammatory properties. This study aimed to investigate the oral administration of WDL as a potential treatment for particle-induced osteolysis using a well-established mice calvarial disease model.
Thirty-two C57BL/6 J mice were randomized into four groups: Sham, vehicle, osteolysis group with oral WDL treatment for 4 weeks (WDL 4w), and osteolysis group treated for 8 weeks (WDL 8w). Micro-CT was used to quantitatively analyze the bone mineral density (BMD), bone volume/tissue volume (BV/TV) and trabecular bone thickness (Tb.Th). Osteoclast numbers were also measured from histological slides by two investigators who were blind to the treatment used.
The results from micro-CT observation showed that BMD in the WDL 8w group improved significantly over the vehicle group (p < 0.05), but there was no significant difference between WDL 4w and 8w for BV/TV and Tb.Th. Osteoclast numbers in the WDL 4w group were also lower than the vehicle group (p < 0.05), but the difference between WDL 8w and 4w groups was not significant.
Particle-induced osteolysis is an inevitable long-term complication after TJR. The results of this animal study indicate that an oral administration of WDL can help reduce the severity of osteolysis without adverse effects.
溶骨症是影响全关节置换术（TJR）患者的最常见临床并发症之一。韦德尔内酯（WDL）是一种来源于三裂叶蟛蜞菊的香豆素化合物，已被证明具有抗炎作用。本研究旨在使用已建立的小鼠颅骨疾病模型，研究 WDL 的口服给药作为治疗颗粒诱导性溶骨症的潜在方法。
将 32 只 C57BL/6J 小鼠随机分为四组：假手术组、载体组、溶骨组（给予 WDL 口服治疗 4 周，WDL 4w）和溶骨组（给予 WDL 口服治疗 8 周，WDL 8w）。采用微 CT 对骨矿物质密度（BMD）、骨体积/组织体积（BV/TV）和小梁骨厚度（Tb.Th）进行定量分析。还通过两位对所用治疗方法不知情的研究者从组织学切片中测量破骨细胞数量。
微 CT 观察结果表明，WDL 8w 组的 BMD 明显高于载体组（p<0.05），但 WDL 4w 组与 8w 组的 BV/TV 和 Tb.Th 无显著差异。WDL 4w 组的破骨细胞数量也低于载体组（p<0.05），但 8w 组与 4w 组之间的差异无统计学意义。
颗粒诱导性溶骨症是 TJR 后不可避免的长期并发症。这项动物研究的结果表明，WDL 的口服给药可以帮助减轻溶骨症的严重程度，而没有不良反应。
